Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-051 8, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1 -Infected Individuals.

The article reports on the study covering the antiretroviral activity and safety of MK-0518 as monotherapy for 10 days in antiretroviral therapy-naive HIV-1 infected patients. It presents the data from the two-part study showing MK-0518's longer term combination therapy phase trial after the monotherapy phase. Results showed the sustainability of antiretroviral activity, optimum pharmacokinetics profile, and the short-term tolerability of MK-0518 when distributed at different dosing levels.